Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Blood (2018) 131 (21): 2357–2366.

https://doi.org/10.1182/blood-2017-12-820910

Published: 2018

Includes: Supplemental data

Journal Articles

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Christian W. Eskelund, Christina Dahl, Jakob W. Hansen, Maj Westman, Arne Kolstad, Lone B. Pedersen, Carmen P. Montano-Almendras, Simon Husby, Catja Freiburghaus, Sara Ek, Anja Pedersen, Carsten Niemann, Riikka Räty, Peter Brown, Christian H. Geisler, Mette K. Andersen, Per Guldberg, Mats Jerkeman, Kirsten Grønbæk

Blood (2017) 130 (17): 1903–1910.

https://doi.org/10.1182/blood-2017-04-779736

Published: 2017

Includes: Supplemental data

Journal Articles

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Arne Kolstad, MD PhD, Lone B Pedersen, Christian Winther Eskelund, Simon Husby, MD, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, MD PhD, Niels S. Andersen, MD PhD, Peter de Nully Brown, MD PhD, Christian H Geisler

Blood (2016) 128 (22): 146.

https://doi.org/10.1182/blood.V128.22.146.146

Published: 2016

Journal Articles

Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

Christian Winther Eskelund, Jakob W Hansen, Maj Karoline Westman, MSc, Catja Freiburghaus, PhD, Sara Ek, PhD, Lone B Pedersen, Mette K Andersen, Riikka Räty, Arne Kolstad, Mats Jerkeman, Peter de Nully Brown, MD PhD, Christian H Geisler, Kirsten Groenbaek

Blood (2016) 128 (22): 1095.

https://doi.org/10.1182/blood.V128.22.1095.1095

Published: 2016

Journal Articles

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Blood (2015) 125 (17): 2669–2677.

https://doi.org/10.1182/blood-2014-06-584193

Published: 2015

Includes: Supplemental data

Journal Articles

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Blood (2008) 112 (7): 2687–2693.

https://doi.org/10.1182/blood-2008-03-147025

Published: 2008

Journal Articles

Successful Preemptive Treatment of Molecular Relapse after Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

Niels S. Andersen, MD, Lone B. Pedersen, Anna Laurell, MD, Erkki Elonen, MD, Arne Kolstad, MD, Christian H. Geisler, MD

Blood (2007) 110 (11): 1281.

https://doi.org/10.1182/blood.V110.11.1281.1281

Published: 2007

Journal Articles

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Blood (2007) 110 (11): LB1.

https://doi.org/10.1182/blood.V110.11.LB1.lb1

Published: 2007

Journal Articles

Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.

Christian H. Geisler, MD, PhD, Erkki Elonen, MD, Ph.D, Arne Kolstad, MD, Ph.D, Anna Laurell, MD, Ph.D, Lone B. Pedersen, B of Sc, Niels S. Andersen, MD, Ph.D, Mats Jerkeman, MD, Ph.D, Marie Nordstrom, MD, Ph.D, Grethe F. Lauritzen, MD, Ph.D, Elisabeth Ralfkiaer, MD, Ph.D, Maans Akerman, MD, Ph.D, Christer Sundstrom, MD, Ph.D, Ruth Langholm, MD, Ph.D, Marja-Liisa Karjalainen-Lindsberg, MD, Ph.D, Outti Kuittinen, MD, Ph.D, Mikael Eriksson, MD, Ph.D, Nordic Lymphoma Group

Blood (2005) 106 (11): 2429.

https://doi.org/10.1182/blood.V106.11.2429.2429

Published: 2005

Journal Articles

Validation of the Prognostic Significance of the Disease Specific Gene CLLU1 in Chronic Lymphocytic Leukemia.

Par Josefsson, MD, Jesper Jurlander, MD, PhD, Christian H. Geisler, MDD.MS, Lone B. Pedersen, Lone Bach, Mette K. Andersen, MD, Henrik Leffers, MS, Anne Mette Buhl, PhD

Blood (2005) 106 (11): 709.

https://doi.org/10.1182/blood.V106.11.709.709

Published: 2005

Journal Articles

Nordic Mantle Cell Lymphoma (MCL) Project: Prolonged Follow-Up of 86 Patients Treated with BEAM/BEAC + PBSCT Confirms That Addition of High-Dose Ara-C and Rituximab to CHOP Induction + In-Vivo Purging with Rituximab Increases Clinical and Molecular Response Rates, PCR-Neg. Grafts, Failure-Free, Relapse-Free and Overall Survival.

Christian H. Geisler, MD, PhD, Erkki Elonen, MD, PhD, Arne Kolstad, MD, PhD, Anna Laurell, MD, PhD, Niels S. Andersen, MD, PhD, Lone B. Pedersen, Mats Jerkeman, MD, PhD, Marie Nordstroem, MD, PhD, Grete F. Lauritzen, MD, PhD, Elisabeth Ralfkiaer, MD, PhD, Maans Aakerman, MD, PhD, Christer Sundstroem, MD, PhD, Ruth Langholm, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, MD, PhD

Blood (2004) 104 (11): 8.

https://doi.org/10.1182/blood.V104.11.8.8

Published: 2004

Journal Articles

A Novel and Disease Specific Gene in Chronic Lymphocytic Leukemia.

Anne Mette Buhl, PhD, Jesper Jurlander, MD, PhD, Lone B. Pedersen, Par Josefsson, MD, Christian H. Geisler, MD, DMsc, Henrik Leffers, MSc

Blood (2004) 104 (11): 770.

https://doi.org/10.1182/blood.V104.11.770.770

Published: 2004

Journal Articles

Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures

Niels S. Andersen, Jørgen K. Larsen, Jette Christiansen, Lone B. Pedersen, Nicolaj S. Christophersen, Christian H. Geisler, Jesper Jurlander

Blood (2000) 96 (6): 2219–2225.

https://doi.org/10.1182/blood.V96.6.2219

Published: 2000

NARROW

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Successful Preemptive Treatment of Molecular Relapse after Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.

Validation of the Prognostic Significance of the Disease Specific Gene CLLU1 in Chronic Lymphocytic Leukemia.

A Novel and Disease Specific Gene in Chronic Lymphocytic Leukemia.

Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only